# Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction

> **NCT00025415** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 60 (actual)

## Conditions studied

- Accelerated Phase Chronic Myelogenous Leukemia
- Acute Undifferentiated Leukemia
- AIDS-related Peripheral/Systemic Lymphoma
- AIDS-related Primary CNS Lymphoma
- Anaplastic Large Cell Lymphoma
- Angioimmunoblastic T-cell Lymphoma
- Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Blastic Phase Chronic Myelogenous Leukemia
- Childhood Myelodysplastic Syndromes
- Chronic Eosinophilic Leukemia
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Chronic Myelomonocytic Leukemia
- Chronic Neutrophilic Leukemia
- Chronic Phase Chronic Myelogenous Leukemia
- de Novo Myelodysplastic Syndromes
- Essential Thrombocythemia
- Extramedullary Plasmacytoma
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Gastrointestinal Stromal Tumor
- Intraocular Lymphoma
- Isolated Plasmacytoma of Bone
- Meningeal Chronic Myelogenous Leukemia
- Monoclonal Gammopathy of Undetermined Significance
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
- Nodal Marginal Zone B-cell Lymphoma
- Polycythemia Vera
- Previously Treated Myelodysplastic Syndromes
- Primary Central Nervous System Non-Hodgkin Lymphoma
- Primary Myelofibrosis
- Primary Systemic Amyloidosis
- Progressive Hairy Cell Leukemia, Initial Treatment
- Prolymphocytic Leukemia
- Recurrent Adult Acute Lymphoblastic Leukemia
- Recurrent Adult Acute Myeloid Leukemia
- Recurrent Adult Burkitt Lymphoma
- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Adult Diffuse Mixed Cell Lymphoma
- Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
- Recurrent Adult Hodgkin Lymphoma
- Recurrent Adult Immunoblastic Large Cell Lymphoma
- Recurrent Adult Lymphoblastic Lymphoma
- Recurrent Adult T-cell Leukemia/Lymphoma
- Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
- Recurrent Mycosis Fungoides/Sezary Syndrome
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Hairy Cell Leukemia
- Refractory Multiple Myeloma
- Relapsing Chronic Myelogenous Leukemia
- Secondary Acute Myeloid Leukemia
- Secondary Myelodysplastic Syndromes
- Small Intestine Lymphoma
- Splenic Marginal Zone Lymphoma
- Stage IV Adult Burkitt Lymphoma
- Stage IV Adult Diffuse Large Cell Lymphoma
- Stage IV Adult Diffuse Mixed Cell Lymphoma
- Stage IV Adult Diffuse Small Cleaved Cell Lymphoma
- Stage IV Adult Hodgkin Lymphoma
- Stage IV Adult Immunoblastic Large Cell Lymphoma
- Stage IV Adult Lymphoblastic Lymphoma
- Stage IV Adult T-cell Leukemia/Lymphoma
- Stage IV Chronic Lymphocytic Leukemia
- Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma
- Stage IV Grade 1 Follicular Lymphoma
- Stage IV Grade 2 Follicular Lymphoma
- Stage IV Grade 3 Follicular Lymphoma
- Stage IV Mantle Cell Lymphoma
- Stage IV Marginal Zone Lymphoma
- Stage IV Mycosis Fungoides/Sezary Syndrome
- Stage IV Small Lymphocytic Lymphoma
- T-cell Large Granular Lymphocyte Leukemia
- Unspecified Adult Solid Tumor, Protocol Specific
- Untreated Adult Acute Lymphoblastic Leukemia
- Untreated Adult Acute Myeloid Leukemia
- Untreated Hairy Cell Leukemia
- Waldenström Macroglobulinemia

## Interventions

- **DRUG:** imatinib mesylate
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00025415
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** 2005-01
- **Final completion:** —
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2013-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00025415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00025415, "Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00025415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*